We guide our clients through all phases of the R&D value chain, from early drug discovery and investigational new drug (IND) progression to clinical development. We also support scientific writing for regulatory documents required for marketing authorisation. Our extensive experience in supporting multidisciplinary drug discovery and development teams in the pharmaceutical industry allows us to integrate seamlessly into your project team or operate as a standalone function. We provide our services to academia, CROs, biotechnological and pharmaceutical companies, and life science venture capital funds.
Our service portfolio includes:
We also offer scientific writing services, including study reports and DMPK sections of IND (Investigational New Drug), IMPD (Investigational Medicinal Product Dossier), IB (Investigator's Brochure) or briefing books. Our DMPK experts inform the design of clinical trials by predicting the human pharmacokinetics of your drug candidate using allometric scaling and other methodologies. They estimate efficacious doses based on pre-defined exposure targets and evaluate in vitro drug–drug interactions (DDI) using basic and mechanistic static modelling. This helps ensure appropriate starting doses and concomitant medications for your trials.